Nano Drug Delivery System R&D Services

Nano Drug Delivery System (NDDS) R&D Services encompass a comprehensive suite of technical solutions focused on the design, development, optimization, and validation of drug delivery platforms utilizing nanomaterials—defined as materials with at least one dimension in the 1–100 nm scale range. These services are tailored to address inherent limitations of conventional drug delivery, including poor bioavailability, non-specific tissue targeting, and systemic toxicity, by leveraging the unique size-dependent properties of nanomaterials such as enhanced permeability and retention (EPR) effect in tumor tissues. As research-focused services, NDDS R&D Services span the pre-clinical research lifecycle, from early-stage feasibility assessment and nanocarrier design to in vitro and preclinical research validation and scalable process development for research purposes. They serve pharmaceutical R&D teams, biotech firms, and academic research institutions in advancing novel therapeutic research toward preliminary application. The core objective of these services is to engineer nanosystems that improve drug solubility, control release kinetics, enhance targeted accumulation at disease sites, and minimize adverse effects in research settings, thereby boosting the potential of therapeutic candidates in experimental studies.

Size-Dependent Biological Interactions of Nanocarriers

The biological behavior of nanocarriers is inherently determined by their particle size, which directly regulates their circulation duration, tissue penetration efficiency, and elimination pathways in preclinical research models. Nanoparticles with a diameter below 200 nm can effectively evade clearance by the reticuloendothelial system (RES) and achieve passive accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect, a key mechanism widely applied in anticancer drug delivery studies. For example, 100 nm doxorubicin-loaded polymer nanoparticles have shown 3–5 times greater tumor accumulation than free doxorubicin formulations in murine breast cancer research models.

In contrast, nanoparticles larger than 200 nm tend to be rapidly removed by macrophages in the liver and spleen under experimental conditions, which restricts their systemic application in scientific research. Besides particle size, surface charge also significantly influences cellular internalization: cationic nanocarriers promote strong electrostatic interactions with negatively charged cell membranes, thus improving cellular uptake, whereas neutral or weakly anionic surfaces can reduce non-specific protein adsorption and RES recognition in research models.

As a typical surface modification strategy, PEGylation (polyethylene glycol coating) of liposomal nanocarriers has been proven to extend their circulation half-life from hours to days in preclinical studies, mainly by reducing opsonization and subsequent macrophage-mediated clearance.

Our Services

CD BioSustainable offers end-to-end Nano Drug Delivery System R&D Services focused on advancing research in precision therapeutics. Our services integrate cutting-edge nanomaterial science, formulation engineering, and preclinical research validation capabilities, supported by a team of experts with extensive experience in translating nano drug delivery technologies from lab to research-scale applications. We collaborate closely with clients to address project-specific research challenges, from optimizing existing formulations for research use to developing novel nanocarrier platforms for difficult-to-deliver drugs (e.g., nucleic acids, hydrophobic small molecules, biologics) in experimental settings. By leveraging state-of-the-art research facilities and proprietary technologies, CD BioSustainable ensures that each project meets rigorous scientific standards, facilitating seamless progression toward advanced research stages and academic or industrial research milestones.

Our Technologies

Nanocarrier Synthesis Technologies for Research

A range of synthesis methods are employed to produce nanocarriers with controlled size, morphology, and properties for research applications. Lipid-based nanocarriers (liposomes, LNPs) are synthesized via thin-film hydration, microfluidic mixing, or high-pressure homogenization—microfluidic mixing is preferred for research-scale production due to its ability to generate uniform particles with narrow size distributions. Polymer-based nanocarriers are prepared using emulsion solvent evaporation, nanoprecipitation, or ionic gelation; for example, PLGA nanoparticles are synthesized via emulsion solvent evaporation for research, where a polymer-drug solution is emulsified in an aqueous phase, followed by solvent evaporation to form solid nanoparticles. Inorganic nanocarriers (gold nanoparticles, silica nanoparticles) are produced using chemical reduction or sol-gel methods; gold nanoparticles, for instance, are synthesized via reduction of chloroauric acid with citrate for research, yielding particles of 10–100 nm in size with tunable optical properties suitable for experimental studies.

Surface Modification and Functionalization Techniques for Research

Surface modification is critical for enhancing nanocarrier biocompatibility, extending circulation time, and enabling targeted delivery in research models. PEGylation is the most widely used surface modification technique in research, involving covalent conjugation of PEG to nanocarrier surfaces to reduce protein adsorption and RES clearance in experimental settings. Ligand functionalization for active targeting in research is achieved via amine-carboxyl coupling, thiol-maleimide conjugation, or biotin-avidin binding; for example, antibodies are conjugated to nanocarrier surfaces via EDC/NHS-mediated coupling of antibody amine groups to carboxyl-modified nanomaterials for research applications. Stimuli-responsive modification in research involves incorporating pH-sensitive (e.g., poly(β-amino ester)) or enzyme-sensitive (e.g., peptide linkers) moieties that degrade or undergo conformational changes in the target microenvironment, triggering drug release in experimental systems.

Advanced Characterization Technologies for Research

State-of-the-art characterization technologies are employed to assess nanocarrier properties with high precision for research purposes. Particle size and zeta potential are measured using DLS, which provides information on hydrodynamic diameter and surface charge—critical for predicting behavior in research models. Morphology is visualized using TEM and SEM, which offer high-resolution images of nanocarrier shape and surface features; cryo-TEM is particularly useful for studying lipid-based nanocarriers in their native hydrated state for research. Drug loading and encapsulation efficiency are quantified using HPLC, LC-MS, or UV-Vis spectroscopy, depending on drug properties for research applications. In vitro drug release is monitored using dialysis bags or flow-through systems, with samples analyzed via chromatographic methods for research data collection. For in vivo research studies, imaging technologies such as fluorescence microscopy, magnetic resonance imaging (MRI), and positron emission tomography (PET) are used to track nanocarrier biodistribution and accumulation in target tissues in experimental models.

In Vitro and Preclinical Research Testing Methodologies

In vitro testing methodologies for research include cell uptake studies using flow cytometry or confocal microscopy to quantify nanocarrier internalization and intracellular distribution. Cytotoxicity is assessed using MTT, CCK-8, or LDH release assays, evaluating cell viability following exposure to nanocarriers with and without drug in research settings. In vitro drug release studies are conducted under physiological conditions (37°C, pH 7.4) or simulated target environments (e.g., pH 5.5 for endosomal release, pH 6.5 for tumor microenvironment) for research purposes. In vivo research testing involves administration of nanocarriers to animal models (mice, rats, rabbits) via relevant routes (intravenous, oral, subcutaneous), followed by collection of blood and tissue samples to determine pharmacokinetic parameters (half-life, AUC, Cmax) and biodistribution in experimental settings. Efficacy studies are performed in disease models (e.g., tumor xenografts, inflammatory bowel disease) to evaluate therapeutic potential in research, while toxicity studies assess organ damage, hematological changes, and immune responses in experimental animals to support further research design.

Material Types Used in Nano Drug Delivery Systems for Research

If you are interested in our services and products, please contact us for more information.

For Research or Industrial Raw Materials, Not For Personal Medical Use!